share_log

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

Benzinga ·  Jul 12 13:18

Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $110 to $115.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment